Αρχική World News GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations

GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations

Findings from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry show that KRASG12C somatic mutations are present in non-small cell lung cancer (NSCLC), colorectal cancer, appendiceal and small bowel cancers, and cancers of unknown primary site, with a mutation frequency of 3 to 14%. Among patients with NSCLC and colorectal cancer, female patients harboured significantly more KRASG12C mutations than male patients. Findings are reported on 14 January 2021 in The New England Journal of Medicine.

The GENIE team searched the distribution of KRASG12C mutations in 32,138 patients with 10 cancer types across race and sex. In total, 2045 patients (6.4%) were Asian, 2355 (7.3%) were Black, and 27,738 (86.3%) were White.

KRASG12C mutations were identified in 1867 samples, most frequently in patients with NSCLC, 1443 of 10,444 (13.8%); 74 of 2105 patients with cancer of unknown primary site (3.5%), 12 of 368 patients with appendiceal cancer (3.3%), 234 of 7402 patients with colorectal cancer (3.2%), and 7 of 223 patients with small-bowel cancer (3.1%).

Among patients with NSCLC, White and Black patient groups were enriched for KRASG12C mutations more than Asians (White patients 13%, Black patients 10.9%, Asian patients 3.6%; p < 0.001).

The GENIE researchers found differences by sex within the same ethnic groups of patients with NSCLC. KRASG12C mutations occurred more often in White female patients than in White male patients with NSCLC (odds ratio 1.4; 95% confidence interval [CI] 1.3 to 1.6; Q < 0.001) and more often in Asian male patients than in Asian female patients (odds ratio 5.2; 95% CI 1.9 to 17.9; Q = 0.01).

Among patients with colorectal cancer, White female patients were enriched for KRASG12C mutations more than White male patients (odds ratio 1.4; 95% CI 1.1 to 1.9; Q = 0.04).

The authors underlined that their data illustrate differences according to sex and ethnic group in the prevalence of KRASG12C mutations in various cancer types and emphasized the importance of mutation analysis of larger numbers of non-White populations and in rare cancers. With the promising efficacy of sotorasib, recruiting patients with cancer types enriched with KRASG12C somatic mutations in future clinical studies will be important.


Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med 2021; 384:185-187.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...